HK-listed Hua Medicine hits 7-mth high on progress of therapy for diabetes

Hua Medicine

19/06/2020 03:22

** Shares of China's clinical-stage drug developer Hua
Medicine  2552.HK  rise as much as 23.7% to HK$6.78 - highest
since Nov. 12 
    ** Stock later trims gains to HK$6.40, still up 16.8% -
heading for biggest intraday pct gain since May 14
    ** Stock ranks sixth biggest pct gainer among all listed
companies on Hong Kong bourse in early trade
    ** Shanghai-based co announces completion of SEED,
Dorzagliatin's Phase III monotherapy trial for use in diabetes
patients  urn:newsml:reuters.com:*:nASA00U7O
    ** Co says it cannot guarantee it will be able to develop,
or ultimately market, Dorzagliatin successfully
    ** As of last close, stock had risen 9.4% so far this year
    ** The Hang Seng China enterprises index  .HSCE  edges down
0.1% and benchmark index  .HSI  slides 0.4%

 (Reuters Messaging: donny.kwok.thomsonreuters.com@reuters.net)